Press coverage about Enzymotec (NASDAQ:ENZY) has trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Enzymotec earned a news impact score of 0.23 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.302532929143 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Enzymotec (NASDAQ ENZY) remained flat at $$11.85 during trading hours on Friday. The company has a market capitalization of $277.62, a P/E ratio of -43.89, a PEG ratio of 3.19 and a beta of 1.22. Enzymotec has a fifty-two week low of $6.30 and a fifty-two week high of $12.35.
Enzymotec (NASDAQ:ENZY) last issued its earnings results on Wednesday, November 15th. The biotechnology company reported $0.04 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.03). Enzymotec had a net margin of 2.32% and a return on equity of 1.24%. equities analysts forecast that Enzymotec will post 0.05 EPS for the current year.
Several research analysts have recently commented on ENZY shares. Wells Fargo & Co raised their price objective on shares of Enzymotec from $9.50 to $12.00 and gave the company a “market perform” rating in a research note on Monday, October 30th. Zacks Investment Research raised shares of Enzymotec from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 17th. BidaskClub lowered shares of Enzymotec from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th. Finally, Jefferies Group reissued a “hold” rating and issued a $11.50 price objective on shares of Enzymotec in a research note on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. Enzymotec has a consensus rating of “Hold” and an average price target of $11.75.
TRADEMARK VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/04/enzymotec-enzy-earns-media-sentiment-score-of-0-23.html.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.